European Commission logo
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-04-30

European randomised multicentre trial on risk-adapted adjuvant chemotherapy in node-negative breast cancer based on selection by tumorbiological prognostic factors

Objective

Objectives:
? Improved effectiveness of systemic adjuvant treatment in node-ne gative breast cancer patients by identification of patients at high risk for rel apse using the tumorbiological factors uPA (urokinase-type plasminogen activator ) and its inhibitor PAI-1.
? Confirmation and validation of the prognostic an d predictive significance of uPA/PAI-1 for breast cancer.
? Feasibility of a pplication to breast cancer patients in daily practic

Brief description
Optimal treatment of breast cancer patients represents a majo r clinical and health problem with a high socio-economic impact. Strong recommen dations ("consensus") were given to offer all patients some kind of adjuvant the rapy. Nevertheless, adjuvant therapy in patients with tumor-free axillary lympho nodes remains a matter of debate, as about 70 % of these patients are cured by s urgery alone. Unselected treatment would lead to an overtreatment in the vast ma jority of these patients. Therefore, high-risk patients should be selected for a djuvant therapy by validated prognostic factors.
Recent basic and clinical canc er research performed at the European level (see BIOMED-I Program: BMHI CT 93-13 46) demonstrated the key role of the tumor-associated protease urokinase-type pl asminogen activator (uPA) and its inhibitor PAI-1 in these processes. The uPA an d PAI- 1 contents of breast cancer tissue are shown to be the strongest independ ent prognostic factors in node-negative disease.
To promote transfer of these recent results derived from basic research into gen eral clinical practice a randomized clinical trial is mandatory. In this trial, node-negative patients with high values of uPA and/or PAI-1 should be randomized to adjuvant chemotherapy (6 cycles CMF) versus observation. Patients with low c ontent of both uPA and PAI-1 will only be observed (< 10% relapse rate). Twelve German clinical and scientific centers take part in the German Pilot Study. Sinc e the start of the study in 1993, about 50 % of the required 1000 patients have been recruited.
To accelerate transfer to clinical application, extension of th e project to the European level by a confirmatory study is mandatory. To reach t hese objectives, 13 clinical/scientific centers in Belgium, Denmark, France, Ire land, Italy, Netherlands, Spain will take part in the study as partners of a Con certed Action. The coordinating study center will be in Hamburg. Central data co llection and randomization will be conducted by the EORTC Central Office - Data Center in collaboration with the Statistical Center for the 12 German centers in Tbingen. A combined analysis of the data acquired by the two statistical center s will be possible after completion of both studies. Quality control of laborato ry data is performed by Department of Experimental Endocrinology (Nijmegen). As industrial partners, 4 companies in Austria, Germany and Sweden involved in deve lopment, production and distribution of reagents, antibodies and laboratory kits of tumor-biological factors will join the proposal.

Keywords:
breast cance r, node-negative patients, risk-adapted adjuvant chemotherapy, tumorbiological p rognostic factors, urokinase-type plasminogen activator, uPA, PAI-1, European mu lticentre trial.

Call for proposal

Data not available

Coordinator

UNIVERSITY OF HAMBURG
EU contribution
No data
Address
52,Martinistrasse 52
20246 HAMBURG
Germany

See on map

Total cost
No data